Vit C prolongs survical and enhances quality of life with cancer patients

Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer

  1. E Cameron and
  2. L Pauling

Abstract

Ascorbic acid metabolism is associated with a number of mechanisms known to be involved in host resistance to malignant disease. Cancer patients are significantly depleted of ascorbic acid, and in our opinion this demonstrable biochemical characteristic indicates a substantially increased requirement and utilization of this substance to potentiate these various host resistance factors. The results of a clinical trial are presented in which 100 terminal cancer patients were given supplemental ascorbate as part of their routine management. Their progress is compared to that of 1000 similar patients treated identically, but who received no supplemental ascorbate. The mean survival time is more than 4.2 times as great for the ascorbate subjects (more than 210 days) as for the controls (50 days). Analysis of the survival-time curves indicates that deaths occur for about 90% of the ascorbate-treated patients at one-third the rate for the controls and that the other 10% have a much greater survival time, averaging more than 20 times that for the controls. The results clearly indicate that this simple and safe form of medication is of definite value in the treatment of patients with acvanced cancer.

 

Articles citing this article

    • S. OHNO,
    • Y. OHNO,
    • N. SUZUKI,
    • G.-I. SOMA,
    • and M. INOUE

    High-dose Vitamin C (Ascorbic Acid) Therapy in the Treatment of Patients with Advanced CancerAnticancer Res 2009 29:809815

    • B. Frei,
    • S. Lawson,
    • M. Levine,
    • Q. Chen,
    • and M. G. Espey
  • Reply to Borst: Randomized clinical trials of high-dose intravenous vitamin C in cancer patients are warrantedProc. Natl. Acad. Sci. USA 2008 105:E96
    • B. Frei
    • and S. Lawson
  • Vitamin C and cancer revisitedProc. Natl. Acad. Sci. USA 2008 105:1103711038
    • Q. Chen,
    • M. G. Espey,
    • A. Y. Sun,
    • C. Pooput,
    • K. L. Kirk,
    • M. C. Krishna,
    • D. B. Khosh,
    • J. Drisko,
    • and M. Levine
  • From the Cover: Pharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in miceProc. Natl. Acad. Sci. USA 2008 105:1110511109
    • Y. Li
    • and H. E. Schellhorn
  • New Developments and Novel Therapeutic Perspectives for Vitamin CJ. Nutr. 2007 137:21712184
    • Q. Chen,
    • M. G. Espey,
    • A. Y. Sun,
    • J.-H. Lee,
    • M. C. Krishna,
    • E. Shacter,
    • P. L. Choyke,
    • C. Pooput,
    • K. L. Kirk,
    • G. R. Buettner,
    • and M. Levine
  • Ascorbate in pharmacologic concentrations selectively generates ascorbate radical and hydrogen peroxide in extracellular fluid in vivoProc. Natl. Acad. Sci. USA 2007 104:87498754
    • S. J. Padayatty,
    • H. D. Riordan,
    • S. M. Hewitt,
    • A. Katz,
    • L. J. Hoffer,
    • and M. Levine
  • Intravenously administered vitamin C as cancer therapy: three cases.CMAJ 2006 174:937942
    • H. Lu,
    • C. L. Dalgard,
    • A. Mohyeldin,
    • T. McFate,
    • A. S. Tait,
    • and A. Verma
  • Reversible Inactivation of HIF-1 Prolyl Hydroxylases Allows Cell Metabolism to Control Basal HIF-1J. Biol. Chem. 2005 280:4192841939
    • Q. Chen,
    • M. G. Espey,
    • M. C. Krishna,
    • J. B. Mitchell,
    • C. P. Corpe,
    • G. R. Buettner,
    • E. Shacter,
    • and M. Levine
  • Pharmacologic ascorbic acid concentrations selectively kill cancer cells: Action as a pro-drug to deliver hydrogen peroxide to tissuesProc. Natl. Acad. Sci. USA 2005 102:1360413609
    • G. M. D’Andrea
  • Use of Antioxidants During Chemotherapy and Radiotherapy Should Be AvoidedCA Cancer J Clin 2005 55:319321
    • K. I. Block
  • Integrative Physician”s PerspectiveIntegr Cancer Ther 2005 4:6164
    • M. J. Gonzalez,
    • J. R. Miranda-Massari,
    • E. M. Mora,
    • A. Guzman,
    • N. H. Riordan,
    • H. D. Riordan,
    • J. J. Casciari,
    • J. A. Jackson,
    • and A. Roman-Franco
  • Orthomolecular Oncology Review: Ascorbic Acid and Cancer 25 Years LaterIntegr Cancer Ther 2005 4:3244
    • A. Vickers
  • Alternative Cancer Cures: “Unproven” or “Disproven”?CA Cancer J Clin 2004 54:110118
    • K. I. Block
    • and M. N. Mead
  • Vitamin C in Alternative Cancer Treatment: Historical BackgroundIntegr Cancer Ther 2003 2:147154
    • J. A. Drisko,
    • J. Chapman,
    • and V. J. Hunter
  • The Use of Antioxidants with First-Line Chemotherapy in Two Cases of Ovarian CancerJ. Am. Coll. Nutr. 2003 22:118123
    • S. J. Padayatty
    • and M. Levine
  • New insights into the physiology and pharmacology of vitamin CCMAJ 2001 164:353355
    • S. J Padayatty
    • and M. Levine
  • Reevaluation of Ascorbate in Cancer Treatment: Emerging Evidence, Open Minds and SerendipityJ. Am. Coll. Nutr. 2000 19:423425
    • P. R. Rosenbaum
  • Discussing Hidden Bias in Observational StudiesANN INTERN MED 1991 115:901905

Share This Post

Supplemental ascorbate in the supportive treatment of cancer: Prolongation of survival times in terminal human cancer E Cameron and L Pauling Abstract Ascorbic acid metabolism is associated with a number of mechanisms known to be involved in host resistance to malignant disease. Cancer patients are significantly depleted of ascorbic acid, and in our opinion this…
&source=WeeksMD">